Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit

用于早期癌症评估的液体活检的竞争前合作：数据管理和协调单位

基本信息

批准号：
10838127
负责人：
Wei Sun
金额：
$ 79.2万
依托单位：
FRED HUTCHINSON CANCER CENTER
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10838127
关键词：
Address Adoption Area Artificial Intelligence Benign Bioinformatics Biological Assay Biological Markers Biometry Biopsy Blood Body Fluids Cancer Center Cancer Detection Cancer Patient Cancerous Caring Cerebrospinal Fluid Clinical Collaborations Collection Common Data Element Communication Communities Community Outreach Computational Biology Computer Analysis Confidence Intervals Data Data Analyses Data Coordinating Center Data Element Data Science Data Storage and Retrieval Detection Development Disease Early Detection Research Network Educational workshop Goals Image Indolent Informatics Leadership Lesion Machine Learning Malignant Neoplasms Manuals Methods Molecular Morbidity - disease rate National Cancer Institute Neoplasm Circulating Cells Patients Performance Population Positioning Attribute Procedures Proteins RNA Reproducibility Reproducibility of Results Research Research Design Research Methodology Research Personnel Research Support Resources Saliva Science Scientific Advances and Accomplishments Screening for cancer Secure Sensitivity and Specificity Somatotype Specimen Sputum Standardization Statistical Data Interpretation Statistical Methods System Techniques Technology Tissues Translational Research Urine Validation Work big data management biomarker development biomarker validation cancer diagnosis cancer type cell free DNA cloud storage curative treatments data centers data management data sharing data standards deep learning design exosome experience extracellular vesicles federated learning improved innovation laboratory experience learning strategy liquid biopsy machine learning model machine learning prediction meetings member minimally invasive molecular imaging mortality multidisciplinary notch protein novel operation outreach pre-clinical premalignant programs prospective protocol development research clinical testing response service coordination statistics symposium tumor tumor DNA validation studies web site

项目摘要

PROJECT SUMMARY Liquid biopsy is a clinical test that involves the analysis of various biomarkers present in the blood or other types of body fluids. It enables the detection of cancer at an earlier stage than traditional imaging or tissue biopsy methods, and thus can lead to reduction of cancer mobility and mortality. As one of the most promising solutions for cancer early detection, liquid biopsy has the potential to revolutionize cancer diagnosis, providing patients with more effective and less invasive care. The liquid biopsy analytes include circulating tumor cells (CTCs), circulating tumor DNA, which is part of cell-free DNA (cfDNA), extracellular vesicles, as well other tumor associated RNAs, proteins and metabolites. These analytes typically have very low levels in blood or other types of body fluid of early-stage cancer patients, leading to difficulties in obtaining reproducible results and low sensitivity and specificity for cancer early detection. While many new assays and techniques have been developed to tackle these challenges, validation of these assays/techniques in different populations and/or cancer types poses many challenges, and these are the main areas of research supported by the liquid biopsy consortium (LBC). As Data Management and Coordinating Unit (DMCU) of LBC, we will support state- of-the-art statistical methods for study design and data analysis, the coordination, implementation, and conduct of collaborative studies across the consortium and work closely with LBC investigators on data analysis by statistical methods, machine Learning modeling and Artificial Intelligence. We will also support consortium coordination and data management, including identification and adoption of standard data elements for liquid biopsy studies. We seek to establish the DMCU as a leading center for innovation and resources in liquid biopsy research, and to enhance, improve and maintain LBC network integration and coordination.

项目概要液体活检是一种临床测试，涉及分析血液或其他物质中存在的各种生物标志物体液的类型。与传统成像或组织相比，它能够在更早阶段检测出癌症活检方法，因此可以导致癌症移动性和死亡率的降低。作为最有前途的企业之一癌症早期检测的解决方案，液体活检有可能彻底改变癌症诊断，提供患者获得更有效、侵入性更小的护理。液体活检分析物包括循环肿瘤细胞 (CTC)、循环肿瘤 DNA（属于无细胞 DNA (cfDNA) 的一部分）、细胞外囊泡以及其他肿瘤相关RNA、蛋白质和代谢物。这些分析物在血液或药物中的含量通常非常低早期癌症患者的其他类型体液，导致难以获得可重复的结果癌症早期检测的敏感性和特异性较低。虽然许多新的检测方法和技术已经开发这些方法是为了应对这些挑战，在不同人群中验证这些测定/技术和/或癌症类型带来了许多挑战，这些是液体支持的主要研究领域活检联盟（LBC）。作为 LBC 的数据管理和协调单位 (DMCU)，我们将支持国家- 用于研究设计和数据分析、协调、实施和进行的最先进的统计方法整个联盟的合作研究，并与 LBC 研究人员密切合作进行数据分析统计方法、机器学习建模和人工智能。我们也将支持财团协调和数据管理，包括识别和采用液体标准数据元素活检研究。我们力求将 DMCU 打造成液体领域领先的创新和资源中心活检研究，并加强、改善和维护LBC网络的整合和协调。